MedImmune COO retiring
Executive Summary
MedImmune Chief Operating Officer Melvin Booth will retire around end of the year, the company tells earnings call Oct. 23. "We do not have any immediate plans to fill the COO position," CEO David Mott said. Booth joined MedImmune in 1998 from Human Genome Sciences (1"The Pink Sheet" Sept. 21, 1998, In Brief)...
You may also be interested in...
Medimmune
Former Syntex Labs President Melvin Booth appointed Medimmune president and COO reporting to Chairman and CEO Wayne Hockmeyer, PhD. Booth joins Medimmune from Human Genome Sciences, where he was president
EU Notified Body Association Takes Steps To Allay EC’s Virtual Audit Fears
The European Commission has reluctantly allowed virtual audits in the context of new MDR and IVDR. The EU notified body association is helping the collective effort to meet its strict requirements.
New UK Biosimilars Pathway Suffers Setback
The UK’s implementation of a new national licensing framework for biosimilars has been pushed back from the start of 2021, with the MHRA citing “intense COVID-19 activities” as the cause of an indefinite delay in the consultation process.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: